| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
Role of TET2 mutations that occur commonly in abnormal hematopoietic stem cells of the myeloid tumors is unclear.
By analyzing TET2 deficient mice, we revealed what changes are occurred in the hematopoietic progenitor cells in which TET2 function is reduced . Application of the result to development of novel therapies for myeloid tumors is expected.
In addition, by using the JAK2V617F transgenic mice and TET2 deficient mice, we revealed that co-existence of TET2 mutations affect "severity of disease" and "enhancement of the onset ability" of JAK2V617F transgenic mice.
|
